Liver fibrosis: Common mechanisms and antifibrotic therapies

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue , 2015, Pages S51-S59

  Schuppan, Detlef ^a,b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ALCOHOL ABSTINENCE; ANGIOGENESIS; ELASTOGRAPHY; EXERCISE; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; LIVER FIBROSIS; MECHANICAL STRESS; MYOFIBROBLAST; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; RISK ASSESSMENT; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STELLATE CELL; TREATMENT RESPONSE; VIRUS HEPATITIS; WEIGHT REDUCTION; ADAPTIVE IMMUNITY; ANIMAL; BLOOD; DIAGNOSTIC IMAGING; IMMUNOLOGY; INNATE IMMUNITY; LIVER CIRRHOSIS;

ADAPTIVE IMMUNITY; ANIMALS; BIOMARKERS; DIAGNOSTIC IMAGING; HUMANS; IMMUNITY, INNATE; LIVER CIRRHOSIS;

EID: 84942816649     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.05.005     Document Type: Short Survey

References (55)

1. Schuppan D., Afdhal N.H. Liver cirrhosis. Lancet 2008, 371:838-851.
2. Friedman S.L., Sheppard D., Duffield J.S., Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013, 5:1-17.
3. Schuppan D., Kim Y.O. Evolving therapies for liver fibrosis. J Clin Invest 2013, 123:1887-1901.
4. Torok N., Dranoff J.A., Schuppan D., Friedman S.L. Strategies and endpoints of antifibrotic drug trials. Hepatology 2015, [Epub ahead of print, PubMed PMID: 25626988]. 10.1002/hep.27720.
5. Mehal W.Z., Schuppan D. Antifibrotic therapies: moving towards clinical translation. Sem Liver Dis 2015, 35:184-198.
6. Friedman S.L., Trautwein C., Schuppan D., Pinzani M. Hepatic fibrosis: concept to treatment. J Hepatol 2015, 62(1S):S15-S24.
7. Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 1990, 10:1-10.
8. Schuppan D., Ruehl M., Somasundaram R., Hahn E.G. Matrix as a modulator of hepatic fibrogenesis. Sem Liver Dis 2001, 21:351-372.
9. Karsdal M.A., Manon-Jensen T., Genovese F., Kristensen J.H., Nielsen M.J., Sand J.M., et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2015, 308:G807-G830. 10.1152/ajpgi.00447.
10. Lowes K.N., Brennan B.A., Yeoh G.C., Olynyk J.K. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999, 154:537-541.
11. Milani S., Herbst H., Schuppan D., Stein H., Surrenti C. Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol 1991, 139:1221-1230.
12. Pinzani M., Milani S., Herbst H., DeFranco R., Grappone C., Gentilini A., et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996, 148:785-800.
13. Omenetti A., Porrello A., Jung Y., Yang L., Popov Y., Choi S.S., et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008, 118:3331-3342.
14. Wang B., Dolinski B.M., Kikuchi N., et al. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology 2007, 46:1404-1410.
15. Patsenker E., Popov Y., Stickel F., et al. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008, 135:660-670.
16. Popov Y., Patsenker E., Stickel F., et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008, 48:453-464.
17. Kuramitsu K., Sverdlov D.Y., Liu S.B., Csizmadia E., Burkly L., Schuppan D., et al. Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol 2013, 183:182-194.
18. Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381:468-475.
19. D'Ambrosio R., Aghemo A., Rumi M.G., Ronchi G., Donato M.F., Paradis V., et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012, 56:532-543.
20. Pellicoro A., Ramachandran P., Iredale J.P., et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014, 14:181-194.
21. Kubes P., Mehal W.Z. Sterile inflammation in the liver. Gastroenterology 2012, 143:1158-1160.
22. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005, 15:56-65.
23. Tacke F., Zimmermann H.W. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 2014, 60:1090-1100.
24. + monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009, 50:261-274.
25. Ramachandran P., Pellicoro A., Vernon M.A., Boulter L., Aucott R.L., Ali A., et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A 2012, 109:E3186-E3190.
26. Popov Y., Sverdlov D.Y., Bhaskar K.R., Sharma A.K., Millonig G., Patsenker E., et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol 2010, 298:G323-G334.
27. Baeck C., Wei X., Bartneck M., Fech V., Heymann F., Gassler N., et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology 2014, 59:1060-1072.
28. Barry-Hamilton V., Spangler R., Marshall D., McCauley S., Rodriguez H.M., Oyasu M., et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010, 16:1009-1017.
29. Popov Y., Schuppan D. Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies. Hepatology 2009, 50:1294-1300.
30. Schuppan D., Pinzani M. Anti-fibrotic therapy: lost in translation?. J Hepatol 2012, 56(Suppl. 1):S66-S74.
31. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
32. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
33. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
34. Procopet B., Berzigotti A., Abraldes J.G., Turon F., Hernandez-Gea V., García-Pagán J.C., et al. Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. J Hepatol 2014, [pii: S0168-8278(14)00925-8.doi: 10.1016/j.jhep.2014.12. 007].
35. Asrani S.K., Talwalkar J.A., Kamath P.S., Shah V.H., Saracino G., Jennings L., et al. Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol 2014, 60:934-939.
36. Popescu A., Sporea I., Sirli R., Bota S., Focsa M., Danila M., et al. The mean values of liver stiffness assessed by Acoustic Radiation Force Impulse elastography in normal subjects. Med Ultrason 2011, 13:33-37.
37. Banerjee R., Pavlides M., Tunnicliffe E.M., Piechnik S.K., Sarania N., Philips R., et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 2014, 60:69-77.
38. Fuchs B.C., Wang H., Yang Y., Wei L., Polasek M., Schuhle D.T., et al. Molecular MRI of collagen to diagnose and stage liver fibrosis. J Hepatol 2013, 59:992-998.
39. Everson G.T., Shiffman M.L., Hoefs J.C., Morgan T.R., Sterling R.K., Wagner D.A., et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2012, 55:1019-1029.
40. Parkes J., Guha I.N., Roderick P., Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006, 44:462-474.
41. Thein H.H., Yi Q., Dore G.J., Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008, 48:418-431.
42. Trocme C., Leroy V., Sturm N., Hilleret M.N., Bottari S., Morel F., et al. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat 2006, 13:643-651.
43. Mayo M.J., Parkes J., Adams-Huet B., Combes B., Mills A.S., Markin R.S., et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008, 48:1549-1557.
44. Fontana R.J., Dienstag J.L., Bonkovsky H.L., Sterling R.K., Naishadham D., Goodman Z.D., et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010, 59:1401-1409.
45. Parkes J., Roderick P., Harris S., Day C., Mutimer D., Collier J., et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010, 59:1245-1251.
46. Liu P., Hu Y.Y., Liu C., Zhu D.Y., Xue H.M., Xu Z.Q., et al. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2002, 8:679-685.
47. Liu P., Hu Y.Y., Liu C., Xu L.M., Liu C.H., Sun K.W., et al. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol 2005, 11:2892-2899.
48. Poupon R.E., Poupon R., Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994, 330:1342-1347.
49. Corpechot C., Carrat F., Bonnand A.M., Poupon R.E., Popon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32:1196-1199.
50. Aithal G.P., Thomas J.A., Kaye P.V., Lawson A., Ryder S.D., Spendlove I., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1176-1184.
51. Ratziu V., Charlotte F., Bernhardt C., Giral P., Halbron M., Lenaour G., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010, 51:445-453.
52. Torres D.M., Jones F.J., Shaw J.C., Williams C.D., Ward J.A., Harrison S.A. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 2011, 54:1631-1639.
53. Ratziu V., de Ledinghen V., Oberti F., Mathurin P., Wartelle-Bladou C., Renou C., et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011, 54:1011-1019.
54. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., et al. nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015, 385(9972):956-965.
55. Chavez-Tapia N.C., Tellez-Avila F.I., Barrientos-Gutierrez T., Mendez-Sanchez N., Lizardi-Cervera J., Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010, CD007340. doi:10.1002/14651858.CD007340.pub2.